4th Quarter - Termination

SLC HEALTH STRATEGIES, LLC for CUBIST PHARMACEUTICALS, INC.

Firm
Client
Income
$60,000
Expenses
—
Terminated
Dec 29, 2014

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

FY 2014 Omnibus HR 3547 FY 2014 Continuing Resolution H J Res 106 PL 113-73 FY 2014 Continuing Resolution H J Res 59 PL 113-67 FY 2015 Budget, H Con Res 96 (no Senate Companion at this time) HJ Res 124 Continuing Appropriations Resolution, 2015 In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs

LobbyistCovered position, as disclosed
SHARON COHEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.J.Res. 59 (113th), H.J.Res. 106 (113th), H.R. 3547 (113th), H.J.Res. 124 (113th), H.Con.Res. 96 (113th)

Pharmacy PHA

Implementation of the "GAIN" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation HR 3742 -- the Antibiotic Development to Advance Patient Treatment Act of 2013 H.R.4187 -- Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 antibiotic product incentives for possible inclusion in the House "21st Century Cures" effort

LobbyistCovered position, as disclosed
SHARON COHEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 4187 (113th), H.R. 3742 (113th)

Health Issues HCR

Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities.

LobbyistCovered position, as disclosed
SHARON COHEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

HR 4302 Protecting Access to Medicare Act of 2014 - Public Law No: 113-93 In the above the specific issues included potential Medicare offsets that might be applied to prescription drugs H.R.4187 -- Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014

LobbyistCovered position, as disclosed
SHARON COHEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4302 (113th), H.R. 4187 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.